Pharmaceuticals company Dr. Reddy's Laboratories announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenues: Rs 80,162 million, change 17% YoY & 4% QoQ. Gross Margin: 59.6%, Q2FY24: 58.7% & Q1FY25: 60.4%. EBITDA: Rs 22,803 million, 28.4% of Revenues. Profit before Tax: Rs 19,167 million, change 2% QoQ. Profit after Tax: Rs 12,553 million, change -15% YoY & 10% QoQ. H1FY25 Financial Highlights: Revenues: Rs 156,889 million, change 15% YoY. Gross Margin: 60.0%, H1FY24: 58.7%. EBITDA: Rs 44,402 million, 2s.3% of Revenues. Profit before Tax: Rs 37,988 million, change 1% YoY. Profit after Tax: Rs 26,473 million, change -8% YoY. Business Highlights: Completed acquisition of the Nicotine Replacement Therapy ('NRT') portfolio outside of the United States and paid upfront cash consideration of GBP 458 million. Operationalized, Dr. Reddy's and Nestle Health Science, in August 2024 to undertake the business of nutraceutical products and supplements in India and Nepal. 49% of the shares in the subsidiary were transferred to Nestle India. Secured Marketing Authorization from the European Commission for our rituximab biosimilar, following a positive opinion from the C_HMP of the European Medicines Agency. Received approval from the USFDA for Investigational New Drug (IND) application for AUR-112, a highly differentiated potent and selective inhibitor of MAL Tl, being developed for the treatment of lymphoid malignancies. Entered into a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan, a novel gastrointestinal drug, in India. G V Prasad, Co-Chairman & MD, Dr. Reddy's Laboratories, said: "We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle, and completed the acquisition of Nicotinell® and related brands. We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation." Result PDF